Pediatric Oncology News

Chimeric antigen receptor T-cell therapy can reduce tumor burden and improve neurologic function for patients with certain brain and spinal cord cancers, a first-in-human clinical trial showed.

One-third of childhood cancer survivors reported high levels of fear of cancer recurrence even decades after treatment, according to results of a cross-sectional analysis.

The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according to a press release.

Industry-sponsored clinical trials have enrolled significantly more participants than federally sponsored trials over the past decade, according to retrospective study results.

A high percentage of childhood survivors do not undergo guideline-recommended monitoring for late effects, according to results of a population-based study.

Bluebird Bio’s lentiviral vector gene therapy Skysona met its primary efficacy endpoint of survival without major functional disability in 81% of boys with early cerebral adrenoleukodystrophy, a recent analysis showed.

A novel drug delivery construct may protect individuals against cisplatin-induced ototoxicity and associated hearing loss.

Young adults with cancer who were eligible for the Affordable Care Act’s dependent care expansion had greatly improved survival times during the first decade of the ACA, an analysis in Cancer showed.

Cincinnati Children’s has retained its distinction as the No. 1 children’s hospital for cancer in the country.